Showing results (141-150 of 279) with videos related to
Sort By:
Pageof 28
Cancers|March 13, 2025
Population-Adjusted Indirect Treatment Comparisons of Repotrectinib Among Patients with ROS1+ NSCLCJürgen Wolf, Sarah Goring, Adam Lee, et al.Clinical Lung Cancer|April 11, 2022
A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to ErlotinibD Ross Camidge, Teresa Moran, Ingel Demedts, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 23, 2017
Excellent Outcomes with Radiosurgery for Multiple Brain Metastases in ALK and EGFR Driven Non-Small Cell Lung CancerTyler P Robin, D Ross Camidge, Kelly Stuhr, et al.Biorxiv : the Preprint Server for Biology|January 7, 2026
Bivalent CD47 Immunotoxin for Targeted Therapy of Lung CancerJihong Ma, Dinoop Ravindran Menon, Zhaohui Wang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2012
Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancerRobert C Doebele, Amanda B Pilling, Dara L Aisner, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 29, 2021
Brain Metastases in EGFR- and ALK-Positive NSCLC: Outcomes of Central Nervous System-Penetrant Tyrosine Kinase Inhibitors Alone Versus in Combination With RadiationNicholas J Thomas, Nathaniel J Myall, Fangdi Sun, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2012
Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumorsJeffrey R Infante, D Ross Camidge, Linda R Mileshkin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2014
Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancerPuneeth Iyengar, Brian D Kavanagh, Zabi Wardak, et al.Clinical Lung Cancer|May 28, 2026
High Programmed Death-Ligand 1 Expression is Associated With a Shorter Progression Free Survival in ALK-Rearranged Lung Cancer Patients Treated With First Line Tyrosine Kinase InhibitorsYunan Nie, Alyse Staley, Trista K Hinz, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2011
Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumorsPasi A Jänne, David S Boss, D Ross Camidge, et al.Pageof 28